Search Results
Jun 29, 2026, 09:30 ET NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS
target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS and AD.About ALSAmyotrophic lateral sclerosis ("ALS") is an incurable
More news about: NeuroSense
Jun 26, 2026, 10:30 ET Epigenetics Market worth $3.92 billion by 2031 | MarketsandMarkets™
studies. Epigenetics tools are being used to analyze DNA methylation, histone modifications, chromatin accessibility, chromatin remodeling, and non-coding RNA regulation for understanding gene expression changes, disease progression, therapeutic response, and target identification. Rising demand for high-throughput,
More news about: MarketsandMarkets
Jun 25, 2026, 10:51 ET Racura Oncology Doses First Patient in Phase 1 HARNESS-1 Trial of RC220 in EGFR-Mutant Non-Small Cell Lung Cancer
in the urgent need to address TKI therapeutic resistance in EGFR-mutant NSCLC. RC220 gives us the opportunity to explore whether targeting G4-DNA and RNA structures, including MYC-associated growth pathways, can delay EGFR TKI resistance arising and support a new therapeutic combination for patients treated
More news about: Racura Oncology Limited
Jun 25, 2026, 10:31 ET Huntington's Disease Market Poised for Significant Growth at a CAGR of 14% During the Forecast Period (2026-2036) Amid Advancements in Disease-Modifying Therapies | DelveInsight
ANX-005 (Annexon), and others.Skyhawk Therapeutics' SKY-0515 is an investigational oral small-molecule RNA modulator developed using Skyhawk's proprietary SKYSTAR RNA-targeting platform. The therapy is designed to lower levels of both huntingtin (HTT) and PMS1 proteins. By targeting PMS1,
More news about: DelveInsight Business Research, LLP
Jun 25, 2026, 09:20 ET NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease
target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS and AD.About NeuroSenseNeuroSense Therapeutics, Ltd. is a late-stage
More news about: NeuroSense
Jun 25, 2026, 09:00 ET Co-Diagnostics Vector Smart® Division Expands Footprint to 21 States
technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
Jun 25, 2026, 08:38 ET Biolevate To Advance AI-Native Drug Discovery Workflows With NVIDIA BioNeMo Agent Toolkit
model-training architectures and GPU-optimized pipelines to accelerate the next generation of its proprietary, RNA-focused models. By significantly improving the prediction of non-coding RNA folding and hybridization, these high-fidelity models will unlock new paradigms for AI-driven patient stratification
More news about: Biolevate
Jun 25, 2026, 08:35 ET Chonnam National University Identifies Dual-Function Rice Gene That Boosts Drought Tolerance and Grain Yield
uncovered an unexpected function of OsFeSOD3. Beyond its antioxidant role, the protein was found to act as a component of the plastid-encoded RNA polymerase (PEP) complex, a molecular machinery essential for chloroplast gene expression and development. Through direct interactions with other PEP-complex
More news about: Chonnam National University
Jun 25, 2026, 08:30 ET Servier Announces First Patient Enrolled in Phase Ib/II Study for the Treatment of a Rare Pediatric Epilepsy Syndrome in the U.S.
assets, regardless of the size of the patient population.Servier's neurology research is concentrated on the small molecules targeting messenger RNA (mRNA), including antisense oligonucleotides (ASOs), as well as pharmacological molecules and monoclonal antibodies.About Servier Pharmaceuticals
More news about: Servier Pharmaceuticals
Jun 24, 2026, 08:00 ET Phosphorex to Host a Virtual Panel Discussion Exploring Targeted Lipid Nanoparticle Development for Extrahepatic Delivery
enable controlled ligand incorporation while maintaining nanoparticle stability and performance.With nearly two decades of experience working with RNA therapeutics, Allen Horhota, PhD, who most recently served as Vice President of Platform and Delivery at Seamless Therapeutics, will moderate the discussion.
More news about: Phosphorex LLC
Jun 23, 2026, 16:05 ET Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
with Nasdaq Listing Rule 5635(c)(4).About Atrium Therapeutics, Inc.Atrium Therapeutics, Inc. (Nasdaq: RNA) is pioneering targeted delivery of ribonucleic acid (RNA) therapeutics to the heart to transform the standard of care for people living with cardiomyopathies. The Company's proprietary
More news about: Atrium Therapeutics
Jun 23, 2026, 11:23 ET WPI Expands NanoFil™ Family with New Syringe Sizes for Ultra-Low-Volume Delivery
complimenting the current on-market 10 and 100µL syringes.As research advances toward increasingly sophisticated therapeutics like gene editing, RNA-based treatments, targeted biologics, and regenerative medicine, the demand for accurate micro delivery continues to grow. WPI's expanded NanoFil™ portfolio
More news about: World Precision Instruments, Inc.
Jun 23, 2026, 07:00 ET Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory
Rare. The Company's research engine is advancing a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue, in the pursuit of future pipeline candidates. Headquartered in Bridgewater, New Jersey, Insmed has offices
More news about: Insmed Incorporated
Jun 22, 2026, 16:04 ET Delphi Diagnostics Announces New Publication Confirming EAI Predicts Benefit from Weekly Paclitaxel in HR+/HER2− Breast Cancer
measures endocrine activity in a breast tumor, and for prognostic use, the Index Score is adjusted for baseline prognosis using molecular subtype genes (RNA4) and clinical factors such as tumor size and regional lymph node involvement. The EAI test has been shown in various studies to be a consistent prognostic
More news about: Delphi Diagnostics Inc
Jun 22, 2026, 09:00 ET EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots
target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS and AD.About ALSAmyotrophic lateral sclerosis ("ALS") is an incurable
More news about: NeuroSense
Jun 22, 2026, 09:00 ET U.S. Biomedical Innovation Leadership at Risk: New Data Show China Rapidly Closing Gap as Clinical Trials and Manufacturing Migrate Abroad
biomedical domains that Cure examined, U.S. institutions lead China with a 45 percent RCR in CRISPR and gene editing publications, 60 percent RCR in RNA therapeutics, and 90 percent RCR in CAR-T and cell therapy. For AI drug discovery publications, the U.S. leads with a 52 percent RCR, yet China leads
More news about: Cure.
Jun 22, 2026, 07:00 ET Labcorp Announces Nationwide Availability of ColoSense®, the First FDA-Approved RNA-Based At-Home Colorectal Cancer Screening Test
First FDA-approved, at-home screening test that uses RNA technology to detect biomarkers associated with colorectal cancer and advanced adenomasDesigned to reduce common barriers to at-home screening with a cleaner, simplified collection experience that minimizes
More news about: Labcorp
Jun 19, 2026, 09:00 ET Fapon Biopharma and MOTE Therapeutics to Present Dual-Platform B-Cell Immunotherapy Franchise at BIO 2026
worldwide.About MOTE TherapeuticsMOTE Therapeutics is a next-generation RNA therapeutics company focused on solving one of the most fundamental bottlenecks in nucleic acid medicine: delivering RNA payloads — particularly circular RNA (circRNA) — to cells and tissues outside the liver. The company's proprietary
More news about: Fapon Biopharma
Jun 19, 2026, 07:30 ET Replicate Bioscience Awarded Grant to Advance srRNA Vaccine Candidates for Tuberculosis
strategy.About Replicate BioscienceReplicate Bioscience is a clinical-stage company amplifying the power of RNA therapeutics by pioneering its novel self-replicating RNA (srRNA) technology to overcome the shortcomings of existing mRNA approaches, with potential improvements in bioactivity,
More news about: Replicate Bioscience
Jun 18, 2026, 09:05 ET Co-Diagnostics Hosts Kingdom of Saudi Arabia Joint Venture CoMira for Unveiling of Future Automated Manufacturing Line
technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
Jun 17, 2026, 08:00 ET Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond
partnerships, licensing transactions and future commercial products. For instance, T7 RNA Polymerase is widely used in molecular biology and biotechnology for in vitro transcription to generate large quantities of RNA, including mRNA for vaccines, probes, and research. Meanwhile, the TEV protease is
More news about: Azitra, Inc.
Jun 16, 2026, 14:00 ET XR and AI Leap into the Future at Augmented World Expo USA 2026 as Expo Hall Opens in Long Beach, CA
[email protected] is showcasing microbeXR, a new VR-based biomedical education game for Meta Quest that transforms complex topics such as DNA, RNA, microbes, and cellular biology into an immersive, mission-driven learning experience. Backed by the National Science Foundation, the platform uses spatial
More news about: AWE (Augmented World Expo)
Jun 16, 2026, 11:04 ET Pew Supports 10 Leading Latin American Scientists
Ph.D.Laboratory of Andrew D.L. Nelson, Ph.D.Boyce Thompson InstituteLaura Gonzalez Garcia, Ph.D., will explore the unique differences in how an RNA modification influences mRNA stability and turnover in plants and humans.Founded in 1948, The Pew Charitable Trusts uses data to make a difference.
More news about: The Pew Charitable Trusts
Jun 16, 2026, 11:04 ET Pew apoia 10 cientistas pioneiros da América Latina
Nelson, Ph.D.Boyce Thompson InstituteLaura Gonzalez Garcia, Ph.D., vai explorar as diferenças únicas na forma como a modificação de RNA influencia a estabilidade e a rotatividade do mRNA em plantas e humanos.Fundada em 1948, a Pew Charitable Trusts usa dados para fazer a diferença.
More news about: The Pew Charitable Trusts
Jun 16, 2026, 11:04 ET Pew Announces 21 New Biomedical Scholars
ear cells boost sound sensitivity.Steve L. Bonilla, Ph.D.The Rockefeller UniversityDr. Bonilla will investigate how RNA molecules fold into three-dimensional structures to drive complex biological processes.Gianni Castiglione, Ph.D.Vanderbilt UniversityDr.
More news about: The Pew Charitable Trusts